Vascular healing in drug-eluting stents: Differential drug-associated response of limus-eluting stents in a preclinical model of stent implantation

EuroIntervention

Volumn 8, Issue 6, 2012, Pages 752-759

  Steigerwald, Kristin ^a   Ballke, Simone ^a   Quee, Shawn Chin ^b   Byrne, Robert A ^a   Vorpahl, Marc ^c   Vogeser, Michael ^d   Kolodgie, Frank ^c   Virmani, Renu ^c   Joner, Michael ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b ABBOTT VASCULAR   (United States)

^c CVPATH INSTITUTE   (United States)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Backbone; Endothelialisation; Sirolimus analogues; Stents; Uniform stent

Indexed keywords

EVEROLIMUS; FIBRIN; RAPAMYCIN; ZOTAROLIMUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG ELUTING STENT; DRUG RELEASE; ENDOTHELIALISATION; ENDOTHELIUM; FIBRIN DEPOSITION; HEALING; ILIAC ARTERY; IMPLANTATION; NONHUMAN; RABBIT; SCANNING ELECTRON MICROSCOPY; STENOSIS;

ANGIOPLASTY, BALLOON; ANIMALS; ANTIGENS, CD31; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; DRUG-ELUTING STENTS; ENDOTHELIAL CELLS; FIBRIN; ILIAC ARTERY; IMMUNOHISTOCHEMISTRY; MALE; METALS; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, SCANNING; MODELS, ANIMAL; NEOINTIMA; PROSTHESIS DESIGN; RABBITS; SIROLIMUS; TIME FACTORS; WOUND HEALING;

EID: 84872138286     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV8I6A115     Document Type: Article

References (25)

1. Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007;115:1051-8.
2. Farb A, Burke AP, Kolodgie FD, Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation. 2003;108:1701-6.
3. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation. 2007;115:2435-41.
4. Virmani R, Guagliumi G, Farb A, Mussmeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109:701-5.
5. Nebeker NR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, Davidson CJ, McKoy JM, Raisch DW, Whisenant BK, Yarnold PR, Belknap SM, West DP, Gage JE, Morse RE, Gligoric G, Davidson L, Feldman MD. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the research on adverse drug events and reports (RADAR) project. J Am Coll Cardiol. 2006;47:175-81.
6. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52:333-42.
7. Farb A, Tang AL, Shroff S, Sweet S, Virmani R. Neointimal responses 3 months after (32)P beta-emitting stent placement. Int J Radiat Oncol Biol Phys. 2000;48:889-98.
8. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. J Am Coll Cardiol. 1992;19:267-74.
9. Carter AJ, Aggarwal M, Kopia GA, Tio F, Tsao PS, Kolata R, Yeung AC, Llanos G, Dooley J, Falotico R. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res. 2004;63:617-24.
10. Nakazawa G, Nakano M, Otsuka F, Wilcox JN, Melder R, Pruitt S, Kolodgie FD, Virmani R. Evaluation of polymer-based comparator drug-eluting stents using a rabbit model of iliac artery atherosclerosis. Circ Cardiovasc Interv. 2011;4:38-46.
11. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol. 2007;27:1500-10.
12. Schwartz RS, Edelman E, Virmani R, Carter A, Granada JF, Kaluza GL, Chronos NA, Robinson KA, Waksman R, Weinberger J, Wilson GJ, Wilensky RL. Drug-eluting stents in preclinical studies: updated consensus recommendations for preclinical evaluation. Circ Cardiovasc Interv. 2008;1:143-53.
13. Camici GG, Steffel J, Amanovic I, Breitenstein A, Baldinger J, Keller S, Lüscher TF, Tanner FC. Rapamycin promotes arterial thrombosis in vivo: implications for everolimus and zotarolimus eluting stents. Eur Heart J. 2010;31:236-42.
14. Nakazawa G, Finn AV, John MC, Kolodgie FD, Virmani R. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol. 2007;100: 36M-44M.
15. Wilson GJ, Huibregtse BA, Stejskal EA, Crary J, Starzyk RM, Dawkins KD, Barry JJ. Vascular response to a third generation everolimus-eluting stent. EuroIntervention. 2010;6:512-9.
16. Tada N, Virmani R, Grant G, Bartlett L, Black A, Clavijo C, Christians U, Betts R, Savage D, Su SH, Shulze J, Kar S. Polymer-free biolimus a9-coated stent demonstrates more sustained initial inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. Circ Cardiovasc Interv. 2010;3:174-83.
17. Byrne RA, Joner M, Kastrati A. Polymer coatings and delayed arterial healing following drug-eluting stent implantation. Minerva Cardioangiol. 2009;57:567-84.
18. Byrne RA, Iijima R, Mehilli J, Pinieck S, Bruskina O, Schömig A, Kastrati A. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv. 2009;2:291-9.
19. Chin-Quee S, Hsu SH, Nguyen-Ehrenreich KL, Tai JT, Abraham GM, Pacetti, Chan YF, Nakazawa G, Kolodgie FD, Virmani R, Ding NN, Coleman LA. Endothelial cell recovery, acute thrombogenicity, and monocyte adhesion and activation on fluorinated copolymer and phosphorylcholine polymer stent coatings. Biomaterials. 2010;31:648-57.
20. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, Kozuma K, Van Langenhove G, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation. 2001;104:2007-11.
21. Sakurai R, Hongo Y, Yamasaki M, Honda Y, Bonneau HN, Yock PG, Cutlip D, Popma JJ, Zimetbaum P, Fajadet J, Kuntz RE, Wijns W, Fitzgerald PJ; ENDEAVOR II Trial Investigators. Detailed intravascular ultrasound analysis of Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial). Am J Cardiol. 2007;100:818-23.
22. Serruys PW, Ong AT, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, Zeiher A, Grube E, Haase J, Thuesen L, Hamm C, Otto-Terlouw PC. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. EuroIntervention. 2005;1:58-65.
23. von Birgelen C, Basalus MW, Tandjung K, van Houwelingen KG, Stoel MG, Louwerenburg JH, Linssen GC, Saïd SA, Kleijne MA, Sen H, Löwik MM, van der Palen J, Verhorst PM, de Man FH. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. J Am Coll Cardiol. 2012;59:1350-61.
24. Palmerini T, Biondi-Zoccai G, Della Riva D, Stettler C, Sangiorgi D, D'Ascenzo F, Kimura T, Briguori C, Sabatè M, Kim HS, De Waha A, Kedhi E, Smits PC, Kaiser C, Sardella G, Marullo A, Kirtane AJ, Leon MB, Stone GW. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379:1393-402.
25. Hwang CW, Levin AD, Jonas M, Li PH, Edelman ER. Thrombosis modulates arterial drug distribution for drug-eluting stents. Circulation. 2005;111:1619-26.